Nanox Debuts ARC System in Europe, Expands AI Capabilities at ECR 2026
Event summary
- Nanox will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at ECR 2026, held March 4-8 in Vienna.
- The company will present new AI solutions, including FDA-cleared HealthCCSng (cardiac) and HealthOST (bone), and introduce two new AI solutions under development.
- Clinical data from the ADOPT study, conducted at NHS hospitals, will highlight the impact of AI-enabled vertebral fracture identification on clinical workflows.
- Nanox.ARC is CE-marked and FDA-cleared, offering 3D imaging at lower cost and reduced radiation dose compared to traditional CT.
The big picture
Nanox's debut of the Nanox.ARC in Europe and expansion of AI capabilities align with broader industry trends toward decentralized, cost-effective diagnostic imaging. The company's focus on preventive healthcare and early disease detection positions it within the growing market for AI-driven medical technologies. Success will depend on demonstrating clinical efficacy and securing widespread adoption across diverse healthcare settings.
What we're watching
- Market Expansion
- Whether Nanox can successfully penetrate European healthcare markets beyond major medical centers.
- Regulatory Progress
- The pace at which Nanox secures additional regulatory clearances for its AI solutions.
- Clinical Adoption
- How quickly NHS and other healthcare systems integrate Nanox.ARC and AI solutions into routine workflows.
Related topics